<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01116050</url>
  </required_header>
  <id_info>
    <org_study_id>03-104</org_study_id>
    <secondary_id>03-104</secondary_id>
    <nct_id>NCT01116050</nct_id>
  </id_info>
  <brief_title>Intrarectal Misoprostol in Postpartum Haemorrhage</brief_title>
  <acronym>HEMOSTOP</acronym>
  <official_title>Second-line Treatment of Post-partum Haemorrhage With Intrarectal Misoprostol: a Multicentre, Double Blind, Randomized Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Caen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postpartum haemorrhage (PPH) remains the major cause of maternal mortality in France. The
      most efficient treatment of severe PPH is sulprostone which is associated with cardiac
      complications. The objective of this study was to assess the efficacy and the safety of
      intrarectal misoprostol for curative postpartum haemorrhage treatment.

      We conducted a multicenter double blind randomized placebo control trial between June 2004
      and December 2007, among consenting women with postpartum haemorrhage and failure to oxytocin
      treatment.

      Our main criteria of judgement was quantification of blood loss and the use of sulprostone
      between the two groups using either misoprostol intrarectal tablets (5X200mg ) or placebo in
      similar opaque introducer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>quantification of blood loss</measure>
    <time_frame>15 minutes after treatment administration</time_frame>
    <description>quantification of blood loss and the use of sulprostone between the two groups using either misoprostol intrarectal tablets (5X200mg ) or placebo in similar opaque introducer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sulprostone Requirement</measure>
    <time_frame>30 minutes after the diagnostic of post-partum hemorrhage</time_frame>
    <description>distribution of blood loss over time, blood loss higher than 500mL after treatment, blood transfusion, changes in haemoglobin concentration and haematocrit levels, recourse to sulprostone, uterine arteries embolizations and hysterectomy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Postpartum Haemorrhage</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MISOPROSTOL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <description>5 tablets of 200 microgram geach intra rectal by opaque introducer</description>
    <arm_group_label>MISOPROSTOL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>5 tablets in opque introducer</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Older than 18 yrs old

          -  Giving birth after 32 Weeks of amenorrhea

          -  Post-partum haemorrhage due to atony

          -  Inefficiency off the first line treatment

          -  Written signed consent form

        Exclusion Criteria:

          -  known allergy to prostaglandin

          -  haemostasis anomalies before labour

          -  anticoagulant treatment

          -  fetal death

          -  accreta or percreta placenta

          -  under 18 years

          -  delivery before 32 weeks of amenorrhea

          -  post-partum bleeding not suspected to be due to atonic uterus
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michel DREYFUS, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Caen</affiliation>
  </overall_official>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2010</study_first_submitted>
  <study_first_submitted_qc>May 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2010</study_first_posted>
  <last_update_submitted>May 19, 2011</last_update_submitted>
  <last_update_submitted_qc>May 19, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2011</last_update_posted>
  <responsible_party>
    <name_title>Monsieur Angel PIQUEMAL</name_title>
    <organization>Caen University Hospital</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Postpartum Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

